INTRODUCTION: Several epidemiologic studies have provided suggestive evidence of a link between coetaneous malignant melanoma (CMM) and breast cancer. The Breast Cancer Linkage Consortium (BCLC) reported approximately 2.6-fold increase in the risk for CMM among BRCA2 carrier families. METHODS: To evaluate the role of BRCA1/2 mutations in CMM, we screened 92 Jewish patients of Ashkenazi origin diagnosed with CMM for the three Ashkenazi founder mutations: 185delAG and 5382insC in the BRCA1 and 6174delT in the BRCA2 gene. Information about personal demography, family history of cancer, and occupational and lifestyle history was collected. RESULTS: Thirty-seven of 92 (40.2%) CMM patients reported a family history of cancer in a first-degree relative. In 14 patients, history of breast cancer (BC) was recorded; however, no family had features associated with BRCA carrier status (i.e., young age at BC onset, history of several BC cases or ovarian cancer in the family). None of the patients were found to carry any of these three mutations. CONCLUSION: Our results suggest a limited role for the three Ashkenazi BRCA founder mutations in CMM risk among the Ashkenazi Jewish population. Therefore, screening patients with CMM for these BRCA1/2 mutations is not warranted.
INTRODUCTION: Several epidemiologic studies have provided suggestive evidence of a link between coetaneous malignant melanoma (CMM) and breast cancer. The Breast Cancer Linkage Consortium (BCLC) reported approximately 2.6-fold increase in the risk for CMM among BRCA2 carrier families. METHODS: To evaluate the role of BRCA1/2 mutations in CMM, we screened 92 Jewish patients of Ashkenazi origin diagnosed with CMM for the three Ashkenazi founder mutations: 185delAG and 5382insC in the BRCA1 and 6174delT in the BRCA2 gene. Information about personal demography, family history of cancer, and occupational and lifestyle history was collected. RESULTS: Thirty-seven of 92 (40.2%) CMM patients reported a family history of cancer in a first-degree relative. In 14 patients, history of breast cancer (BC) was recorded; however, no family had features associated with BRCA carrier status (i.e., young age at BC onset, history of several BC cases or ovarian cancer in the family). None of the patients were found to carry any of these three mutations. CONCLUSION: Our results suggest a limited role for the three Ashkenazi BRCA founder mutations in CMM risk among the Ashkenazi Jewish population. Therefore, screening patients with CMM for these BRCA1/2 mutations is not warranted.
Authors: Sharon Galper; Rebecca Gelman; Abram Recht; Barbara Silver; Anita Kohli; Julia S Wong; Teresa Van Buren; Elizabeth H Baldini; Jay R Harris Journal: Int J Radiat Oncol Biol Phys Date: 2002-02-01 Impact factor: 7.038
Authors: Marcia S Brose; Timothy R Rebbeck; Kathleen A Calzone; Jill E Stopfer; Katherine L Nathanson; Barbara L Weber Journal: J Natl Cancer Inst Date: 2002-09-18 Impact factor: 13.506
Authors: L Kadouri; D F Easton; S Edwards; A Hubert; Z Kote-Jarai; B Glaser; F Durocher; D Abeliovich; T Peretz; R A Eeles Journal: Br J Cancer Date: 2001-07-06 Impact factor: 7.640
Authors: L Kadouri; Z Kote-Jarai; A Hubert; F Durocher; D Abeliovich; B Glaser; T Hamburger; R A Eeles; T Peretz Journal: Br J Cancer Date: 2004-05-17 Impact factor: 7.640
Authors: Ophira M Ginsburg; Charmaine Kim-Sing; William D Foulkes; Parviz Ghadirian; Henry T Lynch; Ping Sun; Steven A Narod Journal: Fam Cancer Date: 2010-12 Impact factor: 2.375
Authors: Hui Deng; Jing Liu; Yu Deng; Gangwen Han; Yiqun G Shellman; Steven E Robinson; John J Tentler; William A Robinson; David A Norris; Xiao-Jing Wang; Qinghong Zhang Journal: J Invest Dermatol Date: 2013-01-10 Impact factor: 8.551
Authors: Tadeusz Dębniak; Rodney J Scott; Bohdan Górski; Bartłomiej Masojć; Andrzej Kram; Romuald Maleszka; Cezary Cybulski; Katarzyna Paszkowska-Szczur; Aniruddh Kashyap; Dawid Murawa; Karolina Malińska; Magdalena Kiedrowicz; Emilia Rogoża-Janiszewska; Helena Rudnicka; Jakub Deptuła; Paweł Domagała; Wojciech Kluźniak; Marcin R Lener; Jan Lubiński Journal: PLoS One Date: 2018-10-04 Impact factor: 3.240